10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Alprazolam

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Alprazolam

Alprazolam

Class : A

Show all info

Print

Contact us

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].

  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.

  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.

  4. Xanor (alprazolam). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-03-10, cited 2023-11-21]

  5. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  6. Kristjánsson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers Differences between genders. Acta Pharm Nord. 1991;3:249-50.

  7. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly Relation to antipyrine disposition. Arch Gen Psychiatry. 1983;40:287-90.

  8. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam Therapeutic implications. Clin Pharmacokinet. 1993;24:453-71.

  9. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-9.

  10. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res. 1997;14:309-15.

  11. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NIRAVAM (alprazolam). Food and Drug Administration [www]. [updated 2005-01-19, cited 2015-10-15].

  12. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XANAX XR (alprazolam). Food and Drug Administration [www]. [updated 2003-01-17, cited 2015-10-15].

  13. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, Nemeroff CB. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology (Berl). 2005;182:414-9.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.
  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.
  4. Xanor (alprazolam). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-03-10, cited 2023-11-21]
  5. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  6. Kristjánsson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers Differences between genders. Acta Pharm Nord. 1991;3:249-50.
  7. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly Relation to antipyrine disposition. Arch Gen Psychiatry. 1983;40:287-90.
  8. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam Therapeutic implications. Clin Pharmacokinet. 1993;24:453-71.
  9. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-9.
  10. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res. 1997;14:309-15.
  11. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NIRAVAM (alprazolam). Food and Drug Administration [www]. [updated 2005-01-19, cited 2015-10-15].
  12. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XANAX XR (alprazolam). Food and Drug Administration [www]. [updated 2003-01-17, cited 2015-10-15].
  13. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, Nemeroff CB. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology (Berl). 2005;182:414-9.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]